Intuitive Surgical beats Q3 revenue estimates

Intuitive Surgical

21/10/2025 21:14

Overview

Intuitive Surgical Q3 revenue grows 23% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting operational efficiency

Company repurchased 4 mln shares for $1.92 bln in Q3

Outlook

Company expects 2025 da Vinci procedure growth of 17% to 17.5%

Non-GAAP gross profit margin expected at 67% to 67.5% in 2025

Non-GAAP operating expenses to grow 11% to 13% in 2025

Result Drivers

PROCEDURE GROWTH - Worldwide procedures increased 20%, with da Vinci up 19% and Ion up 52%

SYSTEM PLACEMENTS - 427 da Vinci systems placed, including 240 da Vinci 5 systems

INSTALLED BASE EXPANSION - Installed base of da Vinci systems grew 13%, Ion systems 30%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$2.50 bln
$2.40 bln (24 Analysts)
Q3 Adjusted EPS
Beat
$2.40
$1.98 (22 Analysts)
Q3 EPS
$1.95
Q3 Adjusted Net Income
Beat
$867 mln
$718.60 mln (19 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Intuitive Surgical Inc is $591.00, about 22.4% above its October 20 closing price of $458.47

The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 64 three months ago

Press Release: ID:nGNX7qsWMp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)